{"organizations": [], "uuid": "7955e98aa0a3cbed9338427540326b645cc96bb9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biomarin-announces-first-patient-d/brief-biomarin-announces-first-patient-dosed-in-phase-1-2-study-of-treatment-for-type-of-hemophilia-a-idUSFWN1SM0YV", "country": "US", "domain_rank": 408, "title": "BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.38, "site_type": "news", "published": "2018-05-15T20:39:00.000+03:00", "replies_count": 0, "uuid": "7955e98aa0a3cbed9338427540326b645cc96bb9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biomarin-announces-first-patient-d/brief-biomarin-announces-first-patient-dosed-in-phase-1-2-study-of-treatment-for-type-of-hemophilia-a-idUSFWN1SM0YV", "ord_in_thread": 0, "title": "BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "biomarin", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "biomarin pharmaceutical inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Biomarin Pharmaceutical Inc:\n* BIOMARIN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY EVALUATING VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY IN SEVERE HEMOPHILIA A PATIENTS WITH PRE-EXISTING AAV5 ANTIBODIES Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T20:39:00.000+03:00", "crawled": "2018-05-16T18:58:58.023+03:00", "highlightTitle": ""}